We didn’t administer bisantrene to any of the patients as this...

We didn’t administer bisantrene to any of the patients as this was an investigator sponsored trial. The primary end point of the trial was to get the patients to a complete response (CR) so that they would be eligible for a stem cell transplant. If the patient achieves a CR they then exit the trial and move on to other treatments.

For us on the other side of the world, the current security situation is Israel is hard to understand, but I can say that providing Race with daily update on the health of patients who were once in a clinical trial is not high on the investigator’s priorities. We are informed on how the patients are going out of courtesy when they have time.

The results of this trial would likely enable the approved of bisantrene as a treatment for AML if replicated in a later Phase 3 trial. You can’t really ask for more from a Phase 2 trial.